93618-22-5 Usage
Uses
Used in Pharmaceutical Industry:
Methyl 4-(3-bromophenyl)-2,4-dioxobutanoate is used as a building block for the synthesis of various pharmaceuticals. Its unique structure and reactivity make it suitable for the development of new drugs with improved therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical industry, methyl 4-(3-bromophenyl)-2,4-dioxobutanoate is utilized as a key intermediate for the synthesis of agrochemicals. Its versatility in organic synthesis allows for the creation of novel compounds with potential applications in crop protection and pest control.
Used in Organic Synthesis:
Methyl 4-(3-bromophenyl)-2,4-dioxobutanoate is used as a versatile reagent in organic synthesis. Its 3-bromophenyl group provides a site for further functionalization, enabling the synthesis of complex organic compounds with diverse applications.
Used in Drug Development:
As a potential precursor for the development of new drugs, methyl 4-(3-bromophenyl)-2,4-dioxobutanoate is employed in the design and synthesis of innovative pharmaceutical compounds. Its unique structure and reactivity contribute to the discovery of novel therapeutic agents with improved efficacy and safety profiles.
Check Digit Verification of cas no
The CAS Registry Mumber 93618-22-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,3,6,1 and 8 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 93618-22:
(7*9)+(6*3)+(5*6)+(4*1)+(3*8)+(2*2)+(1*2)=145
145 % 10 = 5
So 93618-22-5 is a valid CAS Registry Number.
93618-22-5Relevant academic research and scientific papers
CYCLIC SULFAMIDE COMPOUNDS FOR TREATMENT OF HBV
-
Page/Page column 50; 54, (2020/03/29)
The present disclosure provides, in part, cyclic sulfamide compounds, pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Page/Page column 46; 47, (2014/10/15)
The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
Protein-tyrosine phosphatase inhibitors and uses thereof
-
Page 18, (2010/02/09)
The present invention is directed to compounds of formula (I), or a pharmaceutically suitable salt or prodrug thereof, which are useful for the selective inhibition of protein tyrosine phosphatase-1B (PTP1B), and are useful for the treatment of disorders caused by overexpressed or altered protein tyrosine phosphatase 1B.
